Ingenix Raises €13m From Sofinnova Partners-Led Syndicate to Scale Modality Fusion, a Novel Architecture for Drug Development
Ingenix’s Biological Reasoning Engine fuses biological data through Modality Fusion, a new architecture for AI in drug development
June 3, 2026